Compare NPKI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | CSTL |
|---|---|---|
| Founded | 1932 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2019 |
| Metric | NPKI | CSTL |
|---|---|---|
| Price | $13.65 | $40.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $14.17 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 544.1K | 335.2K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $259,372,000.00 | ★ $343,530,000.00 |
| Revenue This Year | $26.96 | $2.54 |
| Revenue Next Year | $13.16 | N/A |
| P/E Ratio | $35.83 | ★ N/A |
| Revenue Growth | ★ 25.65 | 10.15 |
| 52 Week Low | $4.76 | $14.59 |
| 52 Week High | $14.00 | $42.18 |
| Indicator | NPKI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 66.90 | 64.41 |
| Support Level | $12.04 | $38.73 |
| Resistance Level | $12.56 | $41.88 |
| Average True Range (ATR) | 0.40 | 1.49 |
| MACD | 0.15 | -0.14 |
| Stochastic Oscillator | 81.82 | 81.05 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.